---
title: "GLP-1 Receptor Agonists Linked to Lower Mortality and Cardiovascular Events in T2D Patients with H"
id: "medrxiv-18-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and-heart-failure-with"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-18-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and-heart-failure-with"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.21.26363576v1?rss=1"
published_at: "2026-09-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLP-1 Receptor Agonists Linked to Lower Mortality and Cardiovascular Events in T2D Patients with H
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-18-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and-heart-failure-with
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.21.26363576v1?rss=1)
- **Published At:** 2026-09-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This retrospective cohort study used TriNetX real-world data to evaluate **GLP1-RA** therapy in patients with **type 2 diabetes (T2D)** and **heart failure with reduced ejection fraction (HFrEF)**. - The analysis identified patients initiated on GLP1-RA between May 13, 2026 and June 6, 2026 and performed one-to-one propensity-score matching with a control group. - Two matched cohorts of 38,879 patients each were formed for comparison. - At one year, GLP1-RA use was associated with lower **all-cause mortality**: 4.2% vs 12% (absolute risk difference -7.8; 95% CI -8.17 to -7.41) and hazard ratio (HR) 0.4 (95% CI 0.34–0.38). - The primary composite outcome (acute myocardial infarction, ischemic stroke, acute heart failure) occurred in 32.5% of the GLP1-RA group versus 48.3% of controls (ARD -15.8; 95% CI -16.47 to -15.11; HR 0.6; 95% CI 0.57–0.60). - The GLP1-RA group also had lower risk across reported secondary outcomes, including the individual components of the composite and any in-hospital encounter. - The authors conclude that in this real-world dataset, **GLP1-RA therapy** was associated with reduced mortality and cardiovascular events in patients with T2D and HFrEF. - The manuscript is a medRxiv preprint and has not been peer reviewed; the study used de-identified secondary data and was exempt from IRB approval per the authors. - Data underlying the analysis are available via the TriNetX Research Network link provided by the authors.
## Clinical Analysis & Structured Key Points
Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists | medRxiv Skip to main content Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists View ORCID Profile Mohammed Al-Nusair , View ORCID Profile Aneesha Maini , View ORCID Profile Shriya Khurana , Jowan Al-Nusair doi: https://doi.org/10.64898/2026.09.21.26363576 Mohammed Al-Nusair 1 Department of Internal Medicine, Georgetown University- MedStar Washington Hospital Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mohammed Al-Nusair For correspondence: mohammed.alnusair99{at}gmail.com Aneesha Maini 2 Department of Internal Medicine, MedStar Georgetown University Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Aneesha Maini Shriya Khurana 1 Department of Internal Medicine, Georgetown University- MedStar Washington Hospital Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Shriya Khurana Jowan Al-Nusair 3 Department of Internal Medicine, USF Health Morsani College of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Glucagon-like peptide-1 receptor agonists (GLP1-RA) improve cardiovascular outcomes in patients with type 2 diabetes (T2D) and obesity, and more recently they have been shown to be beneficial in patients with obesity and heart failure with preserved ejection fraction. Their role in patients with heart failure and reduced ejection fraction (HFrEF) and T2D remains underexplored. Methods: A retrospective cohort study was conducted using data pooled from the TriNetX platform. Patients with T2D and HFrEF who were initiated on GLP1-RA therapy during the period May-13-2026 to Jun-6-2026 were identified. One:one propensity-score matching with controls was performed. Time-to-event analysis was conducted to compare the one-year incidences of all-cause mortality and a primary composite outcome of acute myocardial infarction, ischemic stroke and acute heart failure, between the two matched-cohorts. Secondary outcomes included individual components of the primary composite outcome and any inhospital encounter. Results: Two well-matched cohorts with 38,879 patients in each were formed. Patients treated with GLP1-RAs had a lower incidence of all-cause mortality (4.2% vs. 12%; absolute risk difference [ARD] -7.8, 95% CI -8.17 to -7.41; HR 0.4, 95% CI 0.34─0.38) and the primary composite outcome (32.5% vs. 48.3%; ARD -15.8, 95% CI -16.47 to -15.11; HR 0.6, 95% CI 0.57─0.60) compared to the control group. The GLP1-RA group were also at lower risk of all secondary outcomes compared to the control group. Conclusion: In a real-world study, GLP1-RA therapy was associated with lower risk of all-cause mortality and cardiovascular outcomes in patients with T2D and HFrEF. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The current study is exempt from Institutional Review Board (IRB) approval. All data analyses are secondary analyses of existing data from the TriNetX Research Network that can be accessed at (https://live.trinetx.com/). The study does not involve intervention or interaction with human subjects. All included data are de-identified per the de-identification standard defined in Section 164.514(a) of the HIPAA Privacy Rule. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced are available online at (https://live.trinetx.com/). https://live.trinetx.com/ Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 22, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists Mohammed Al-Nusair , Aneesha Maini , Shriya Khurana , Jowan Al-Nusair medRxiv 2026.09.21.26363576; doi: https://doi.org/10.64898/2026.09.21.26363576 Share This Article: Copy Citation Tools Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists Mohammed Al-Nusair , Aneesha Maini , Shriya Khurana , Jowan Al-Nusair medRxiv 2026.09.21.26363576; doi: https://doi.org/10.64898/2026.09.21.26363576 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (905) Anesthesia (336) Cardiovascular Medicine (4838) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1634) Epidemiology (15986) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7073) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5074) Health Policy (1438) Health Systems and Quality Improvement (1780) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16315) Intensive Care and Critical Care Medicine (1177) Medical Education (674) Medical Ethics (155) Nephrology (727) Neurology (7318) Nursing (370) Nutrition (1087) Obstetrics and Gynecology (1245) Occupational and Environmental Health (1007) Oncology (3625) Ophthalmology (1058) Orthopedics (398) Otolaryngology (458) Pain Medicine (476) Palliative Medicine (140) Pathology (709) Pediatrics (1806) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5927) Public and Global Health (9782) Radiology and Imaging (2438) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (644) Sexual and Reproductive Health (774) Sports Medicine (582) Surgery (783) Toxicology (107) Transplantation (306) Urology (295)
## Related Clinical Research

- [Comparing BMI, Waist Circumference, and BRI for Predicting ASCVD, AF, and Mortality in 1.2M Koreans](https://medichelpline.com/clinical-feed/plos-one-14-prognostic-associations-of-anthropometric-indices-with-major-health-outcomes-a.md)
- [Compare and Contrast: GLP-1 Receptor Agonists Access and Cardiovascular Outcomes](https://medichelpline.com/clinical-feed/endocrine-news-33-compare-and-contrast-as-glucagon-like-peptide-1-receptor-agonist-access-expands-comparative-heart-outcomes-matter.md)
- [New CKM Health Education Resources Enhance Patient Care for Cardiovascular and Kidney Risks](https://medichelpline.com/clinical-feed/aha-news-2-new-cardiovascular-kidney-metabolic-ckm-health-education-helps-clinicians-turn.md)
- [Better hypertension control could avert >518,000 cardiovascular deaths annually in 20 countries](https://medichelpline.com/clinical-feed/aha-news-0-managing-high-blood-pressure-could-prevent-500k-cvd-deaths-annually-in-20.md)
- [Long-term cardiovascular risk after assisted reproductive technology and infertility: nationwide c](https://medichelpline.com/clinical-feed/plos-medicine-0-long-term-risk-of-cardiovascular-disease-after-assisted-reproductive-technology.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.